News
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...
New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Clinical Trials Arena on MSN2d
Perioperative Padcev and Keytruda improves survival in MIBC
P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...
2don MSN
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer
Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback